487 related articles for article (PubMed ID: 28835114)
1. Challenges faced when identifying patients for combination immunotherapy.
Ernstoff MS; Gandhi S; Pandey M; Puzanov I; Grivas P; Montero A; Velcheti V; Turk MJ; Diaz-Montero CM; Lewis LD; Morrison C
Future Oncol; 2017 Aug; 13(18):1607-1618. PubMed ID: 28835114
[TBL] [Abstract][Full Text] [Related]
2. The importance for immunoregulation for long-term cancer control.
Fusi A; Dalgleish A
Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
4. Masterful Antibodies: Checkpoint Blockade.
Lonberg N; Korman AJ
Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
[TBL] [Abstract][Full Text] [Related]
5. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
Schmidt EV
Semin Immunopathol; 2019 Jan; 41(1):21-30. PubMed ID: 30374524
[TBL] [Abstract][Full Text] [Related]
6. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
Marrocco I; Romaniello D; Yarden Y
Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
[TBL] [Abstract][Full Text] [Related]
10. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
12. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
[TBL] [Abstract][Full Text] [Related]
13. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
14. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H
Front Immunol; 2018; 9():1739. PubMed ID: 30100909
[TBL] [Abstract][Full Text] [Related]
15. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Patel SA; Minn AJ
Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
[TBL] [Abstract][Full Text] [Related]
16. Novel Immunotherapy Combinations.
Bashir B; Wilson MA
Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy.
Berger G; Marloye M; Lawler SE
Trends Mol Med; 2019 May; 25(5):412-427. PubMed ID: 30885429
[TBL] [Abstract][Full Text] [Related]
18. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Colombo MP
Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
[TBL] [Abstract][Full Text] [Related]
19. Are peptide vaccines viable in combination with other cancer immunotherapies?
Ohtake J; Sasada T
Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424
[No Abstract] [Full Text] [Related]
20. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]